Should I Buy IMUX? IMUX 2026 Analysis

Should You Buy Immunic Inc (IMUX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.610

1 Day change

0.16%

52 Week Range

1.390

Analysis Updated At

2026/01/29

Immunic Inc (IMUX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. Therefore, it is best to hold off on investing in this stock for now.

Technical Analysis

The MACD histogram is negative (-0.00242) and expanding downward, indicating bearish momentum. RSI is at 34.069, which is neutral but leaning toward oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 0.596), with resistance at R1: 0.702.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analyst ratings remain positive, with a 'Buy' recommendation and price targets of $3 and $8, indicating potential upside in the long term.

Neutral/Negative Catalysts

No recent news or significant events. Financial performance is weak, with negative net income (-$25.58M) and declining EPS (-45.83% YoY). Technical indicators suggest bearish momentum, and no recent trading signals or congress trading data are available.

Financial Performance

In Q3 2025, revenue remained at $0. Net income improved slightly YoY but remains negative at -$25.58M. EPS dropped significantly by -45.83% YoY, reflecting poor profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a 'Buy' rating with price targets of $3 and $8, citing potential advantages of the company's drug pipeline. However, the stock's current price of $0.6143 suggests a significant gap to these targets, indicating high risk.

5 Analyst Rating

Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 4.25 USD with a low forecast of 3 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.609

Low

Averages

4.25

High

Current: 0.609

Low

Averages

4.25

High

H.C. Wainwright

Buy

downgrade

$10 -> $8

AI Analysis

2025-11-14

Reason

H.C. Wainwright

Price Target

$10 -> $8

AI Analysis

2025-11-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Immunic to $8 from $10 and keeps a Buy rating on the shares. The firm adjusted the company's share count post the Q3 report.

Roth Capital

Boobalan Pachaiyappan

Buy

initiated

2025-11-07

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

2025-11-07

initiated

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Immunic with a Buy rating and $3 price target. The firm says the company has "potential best-in-indication advantages" of vidofludimus calcium in relapsing-remitting multiple sclerosis and progressive multiple sclerosis. This is validated by Immunic's Phase 2 data that demonstrated simultaneous anti-inflammation and neuroprotection, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMUX

Unlock Now

IMUX Should I Buy

IMUX Should I Buy

Should You Buy Immunic Inc (IMUX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch